Orlando, FL-If a physician discovers an abnormal prostate gland by digital rectal examination, the patient should be a candidate for biopsy to determine if that finding is a malignancy-even if the patient has a PSA
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.